2016
TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer
Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser M, Shilo K, Ganju R. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget 2016, 9: 33459-33470. PMID: 30323891, PMCID: PMC6173360, DOI: 10.18632/oncotarget.9663.Peer-Reviewed Original ResearchTriple-negative breast cancerTransient receptor potential vanilloid type-2Negative breast cancerTNBC patientsTRPV2 expressionBreast cancerHigher recurrence-free survivalRecurrence-free survivalLimited therapeutic optionsGood prognostic markerEfficacy of chemotherapyNovel therapeutic strategiesNormal breast tissueMouse model studiesFree survivalNegative patientsAggressive diseaseTherapeutic optionsCancer patientsTNBC tumorsPrognostic markerTNBC tissuesTRPV2 activationNovel biomarkersTherapeutic strategies
2015
Risk factors for anthracycline-associated cardiotoxicity
Reinbolt R, Patel R, Pan X, Timmers C, Pilarski R, Shapiro C, Lustberg M. Risk factors for anthracycline-associated cardiotoxicity. Supportive Care In Cancer 2015, 24: 2173-2180. PMID: 26563179, PMCID: PMC4874738, DOI: 10.1007/s00520-015-3008-y.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsAnthracycline cardiotoxicityRisk factorsAlcoholic drinks/weekFemale breast cancer patientsHigher cardiotoxicity riskDrinks/weekModerate alcohol consumptionAnthracycline-associated cardiotoxicityBreast cancer patientsCases of cardiotoxicityMajor alleleEjection fractionPediatric patientsCancer patientsCardiotoxicity riskLower riskTherapeutic strategiesAlcohol consumptionCardiotoxicityMultivariate analysisLogistic regressionPatientsGenomic predictorsSignificant correlation